Leukogene Therapeutics Receives Strategic Funding from SCRA to Accelerate Development of Cancer Immunotherapy Pipeline November 18, 2025
Update provided on Ph 1/2a AERIAL trial of LEU011 in patients with R/R solid tumours November 18, 2025
First Patient Dosed in SANTANA-225 Ph 1/2 Trial of 225Ac-SSO110 in Patients with ES-SCLC or MCC November 18, 2025
NDA accepted; PDUFA Date announced for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs November 18, 2025
Novartis opens new RLT manufacturing facility in California as part of $23B US expansion plan November 18, 2025
Sarah Cannon Research Institute and BMS Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research November 18, 2025
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform November 18, 2025
BostonGene and Kyoto University to develop advanced biological signatures to enhance targeted treatment strategies for ESCC November 18, 2025
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology November 18, 2025
Positive Results Reported from Bezuclastinib PEAK Ph 3 Trial in Gastrointestinal Stromal Tumors (GIST) November 18, 2025
MHRA Approves CTA for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) November 18, 2025
FDA Granted Fast Track Designation for AVZO-1418 for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC November 18, 2025
